A Randomized Controlled Clinical Study Of Cefotetan Disodium For Acute Cystitis And Pyelonephritis

Objective: To evaluate the clinical efficacy and safety of cefotetan disodium in the treatment of acute cystitis and pyelonephritis.Methods: A randomized, single-blind, controlled clinical trial was performed. The experimental group were treated with cefotetan disodium and the control group were treated with cefmetazole sodium. The dosages were 2g for moderate infection and 4g for severe infection, twice a day intravenously. The duration of the treatment was 7-10 days.Results:At the end of the treatment, clinical efficacy rate of two groups were 80.00% and 84.21%. The values of two groups has no significant differences(P=0.732). Bacteriological evaluation: the positive rates of bacteria in the experimental group and the control group were 55.00% and 47.37% respectively, and bacterial eradication rates were 81.82% and 77.78%.There was no significant difference (P> 0.05).Safety results showed that in the experimental group, there were 2 cases of adverse reactions, 1 case of rash, another case of elevated alanine aminotransferase. The rate of adverse reaction was 10.0%. In the control group, there were 2 cases of adverse events, with 1 case of elevated aspartate aminotransferase, and with 1 case of gastrointestinal discomfort. The rate of adverse reaction rate was 13.33%. The incidence of adverse reactions in the two groups showed no statistical significance. These adverse events were mild and not given special treatment, except for 1 patient withdrawal due to rash; the course of treatment for remaining patients were not affected, and the follow-up were normal. The patient with rash was given symptomatic treatment and became normal after drug withdrawal.Conclusion: Cefotetan disodium can be an effective treatment for acute cystitis and pyelonephritis. With fewer side effects, cefotetan disodium could be used for clinical use.